apatinib + nab-paclitaxel

Apatinib + nab-paclitaxel is a combination therapy consisting of two drugs: - **Apatinib** is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and reducing tumor blood supply. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The albumin-bound formulation improves drug delivery and reduces some toxicities compared to conventional paclitaxel. This combination has shown synergistic anti-tumor effects in preclinical models and early clinical studies, particularly in platinum-resistant ovarian cancer, advanced breast cancer (including HER2-positive brain metastases), triple-negative breast cancer, gastric cancer, and pancreatic cancer. The rationale for combining these agents includes enhanced efficacy through dual mechanisms—antiangiogenic activity from apatinib and cytotoxicity from nab-paclitaxel—with the potential to reduce chemotherapy dose-related toxicity without compromising efficacy[1][2][3][5].

Brand names

AitanAbraxane

Other names

apatinib plus nab-paclitaxelapatinib combined with albumin-bound paclitaxelapatinib + albumin-bound paclitaxel